GAITHERSBURG, Md., April 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Mathias Oelke, Ph.D., has been promoted to Chief Scientific Officer. Dr. Oelke is a scientific co-founder of NexImmune and joined NexImmune in 2014.
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here